Bellerophon initiated at Maxim

Bellerophon initiated with a Buy at Maxim. Maxim analyst Caroline Palomeque initiated Bellerophon with a Buy rating and a price target of $3, saying the company’s lead product INOpulse is well positioned in the absence of other “FDA-approved treatment options for pulmonary hypertension associated with Interstitial Lung Disease”. The analyst notes that shares were down significantly in Q3 of 2018 after the company’s phase 3 study in pulmonary arterial hypertension was stopped for futility, but she sees upside from the program’s intact clinical path forward and expectations of more data later this year.
https://thefly.com/landingPageNews.php?id=2853089